Kevin Pfleger

Director, Biomedical and Health Innovation at The University of Western Australia and WA Life Sciences Innovation Hub

Greater Perth Area

About

Professor Pfleger is Director Biomedical and Health Innovation at The University of Western Australia and the WA Life Sciences Innovation Hub. He is also Head of Molecular Endocrinology and Pharmacology at the Harry Perkins Institute of Medical Research (UWA Centre for Medical Research). His laboratory studies the molecular pharmacology of receptors, particularly those important in kidney and lung disorders, cardiovascular disease, diabetes complications and cancer. Additionally, he is Chief Scientific Advisor to Dimerix, a spin-out company from The University of Western Australia. Dimerix is commercialising technologies invented in his laboratory and directed towards drug discovery around receptor heteromers, a new class of drug targets. Dimerix's lead therapy co-invented by Prof Pfleger, DMX-200/Qytovra, is in Phase 3 clinical trials for chronic kidney disease (focal segmental glomerulosclerosis). Prof Pfleger has also co-founded RAGE Biotech Pty Ltd, which is developing new approaches to modulate the receptor for advanced glycation end-products (RAGE), an important target in chronic inflammation. He is an advisor to VeinTech and Pretect Devices. Prof Pfleger was awarded his MA and PhD from Cambridge and Edinburgh Universities respectively, and relocated to Western Australia in October 2002. He was a National Health and Medical Research Council (NHMRC) Peter Doherty Research Fellow (2005-2008), Australian Research Council (ARC) Future Fellow (2011-2014), and NHMRC RD Wright Research Fellow (2015-2018). Prof Pfleger is Chair of Biodesign Australia and Perth Biodesign. He was also Founding Co-Director of the Australian Clinical Entrepreneur Program, Deputy Director of the ARC Centre for Personalised Therapeutics Technologies, President of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists and member of the REDI Steering Committee. He is currently a member of the International Advisory Group of the British Pharmacological Society, of which he is a Fellow, the Sector Advisory Panel for the WA Health and Medical Research Strategy 2023-2033, and the Future Health Research and Innovation Fund Innovation Expert Committee. Prof Pfleger's recent accolades include the British Pharmacological Society Novartis Prize 2016, 2017 40under40 Intrapreneur Category winner and City of Perth Strategic Alliance Award, UWA Innovation Champion 2018, and 2018 ASCEPT Award for outstanding contribution and leadership as Chair of the Scientific Advisory Committee 2017-2018.

Experience

  • The University of Western Australia (23 yrs 10 mos)
    • Director Biomedical and Health Innovation
      Jun 2022 - Present · 4 yrs 2 mos

    • Professor
      Apr 2019 - Present · 7 yrs 4 mos

    • Director Biomedical Innovation
      Aug 2019 - Jun 2022 · 2 yrs 11 mos

  • WA Life Sciences Innovation Hub (7 yrs 7 mos)
    • Director Biomedical and Health Innovation
      Jun 2022 - Present · 4 yrs 2 mos

    • Member of Future Health Research and Innovation Fund Innovation Expert Committee
      Dec 2024 - Present · 1 yr 8 mos

    • Member of Health and Medical Life Sciences Industry Advisory Group
      Jan 2024 - Present · 2 yrs 7 mos

  • Biodesign Australia (4 yrs 7 mos)
    • Member of APAC Biodesign Alliance Steering Committee
      Oct 2024 - Present · 1 yr 10 mos

    • Chair of Steering Committee
      2022 - Present · 4 yrs 7 mos

  • Perth Biodesign (9 yrs 7 mos)
    • Chair of Executive Committee and Strategic Advisory Board
      2019 - Present · 7 yrs 7 mos

    • Chair of Executive Committee
      2017 - 2019 · 2 yrs

  • Harry Perkins Institute of Medical Research (23 yrs 10 mos)
    • Head, Molecular Endocrinology and Pharmacology
      Oct 2013 - Present · 12 yrs 10 mos

    • Member of Research Leadership Team
      Oct 2020 - Present · 5 yrs 10 mos

    • Impact Advisor
      Oct 2020 - Sep 2024 · 4 yrs